BRAF and breast carcinoma: On the one hand, this is consistent with an earlier finding that BRCA1-mutant breast cancer cell lines do not usually harbor activating mutations in RAS and BRAF oncogenes26, which normally make cells susceptible to MEK inhibitors29, 30, 31.